December begins with World AIDS Day, an initiative to increase awareness of this now-controllable disease. Last week, the WHO warned that measles cases have risen by 30 percent worldwide, with Latin America and Europe reporting the largest growth in cases. AstraZeneca to launch molecular diagnostics for lung cancer and Bayer informed that it will cut 12,000 jobs.
In Mexico, COFEPRIS released its last medication package permitting the sale of 34 molecules. The council also came under fire after a report indicated that it had failed to inform patients on the dangers of the medical devices they used.
Mexico Health Review spoke to RM Pharma’s Melissa Rosales on the possibilities Mexico has for clinical research.
Now, jump into last week’s highlights:
COFEPRIS releases 12th medication package, allowing for the commercialization in Mexico of 34 new products. The package includes eight biotechnological drugs and five orphan drugs.
The organization Mexicans against Corruption and Impunity warned that Mexicans are not given enough information on the safety of the medical devices they use. The organization claimed that COFEPRIS was not fully transparent in providing information on defective products that had already been removed from other markets.
Analyst from real estate developer CBRE Group claimed that the healthcare sector will lead in infrastructure demand for the next five years in Mexico and the US.
Saturday December 1 was World AIDS Day, which aims to bring people together in the fight against HIV and commemorate those who died from the disease.
WHO warns that measles cases increased over 30 percent from 2016, mainly in Latin America and Europe caused in part by parents who refuse to vaccinate their children.
Bayer to cut 12,000 jobs following its takeover of Monsanto. The German pharmaceutical will also divest its Dr. Scholl and Coppertone brands, which had acquired from Merck in 2014.
AstraZeneca partnered with Belgian Biocartis Group to develop molecular diagnostics for lung cancer.